Pembro Plus Chemo Now for First-Line Metastatic Squamous NSCLC Pembro Plus Chemo Now for First-Line Metastatic Squamous NSCLC
The FDA has granted approval for immunotherapy with pembrolizumab in combination with chemotherapy to be used first-line in metastatic squamous nonsmall cell lung cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer